MCM
INFI

Matarin Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Matarin Capital Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-26,796
Closed -$293K – 236
2015
Q2 		$293K Sell
26,796
-82,167
-75% -$1.05M 0.08% 179
2015
Q1 		$1.52M Buy
108,963
+60,950
+127% +$932K 0.46% 109
2014
Q4 		$811K Buy
+48,013
New +$699K 0.36% 118

Other funds holding INFI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Matarin Capital Management's INFI Position: Q3 2015 in Review

Matarin Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2015, closing a stake of 26,796 shares — an estimated $293K sold.

Matarin Capital Management first reported a position in INFI in Q4 2014 and held it in 3 quarters. The position peaked at $1.52M in Q1 2015. 129 funds tracked by Wall St. Rank hold INFI as of Q3 2015.

  • Matarin Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Matarin Capital Management sold 26,796 Infinity Pharmaceuticals, Inc. shares in Q3 2015, an estimated $293K.
  • Matarin Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
  • Matarin Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $1.52M in Q1 2015.
  • 129 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2015.

Based on Matarin Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.